Table 5.
Metabolites most significantly different between patients who waste and those who do not
| Metabolite | Pathway/type | P (adjusted) | W/NW d1 | W/NW d3 | W/NW d7 | |
|---|---|---|---|---|---|---|
| Lipids | ||||||
| Methylmalonate | Fatty acid | 1.6 E‐04 | 1.44 | 1.32 | 1.36 | |
| 3‐Hydroxybutyrylcarnitine | Acyl carnitine | 6.1 E‐04 | 1.03 | 0.97 | 1.18 | |
| 1‐(1‐Enyl‐palmitoyl)‐2‐linoleoyl‐GPE (P‐16:0/18:2)* | Plasmalogen | 1.4 E‐03 | 0.91 | 0.58 | 0.84 | |
| Acetylcarnitine (C2) | Acyl carnitine | 2.2 E‐03 | 0.96 | 0.97 | 1.41 | |
| 1‐Stearoyl‐2‐linoleoyl‐GPI (18:0/18:2) | Phosphatidylinositol | 6.1 E‐03 | 1.19 | 1.16 | 1.49 | |
| 2‐Aminooctanoate | Fatty acid, amino | 7.4 E‐03 | 0.89 | 1.14 | 0.98 | |
| 1‐Stearoyl‐2‐linoleoyl‐GPC (18:0/18:2)* | Phosphatidylcholine | 7.4 E‐03 | 1.03 | 1.08 | 1.15 | |
| Malonylcarnitine | Acyl carnitine | 7.9 E‐03 | 0.98 | 0.70 | 1.46 | |
| 1,2‐Dilinoleoyl‐GPC (18:2/18:2) | Phosphatidylcholine | 7.9 E‐03 | 1.05 | 1.13 | 1.27 | |
| 3‐Methylglutarate/2‐methylglutarate | Fatty acid, dicarboxylate | 9.6 E‐03 | 0.93 | 0.60 | 1.13 | |
| Amino acids | ||||||
| N‐Acetyl‐1‐methylhistidine* | Histidine | 4.7 E‐05 | 2.12 | 3.24 | 4.16 | |
| N‐Acetylcitrulline | Arginine/proline | 1.6 E‐04 | 2.10 | 1.70 | 1.35 | |
| N‐Acetylglutamine | Glutamate | 1.9 E‐04 | 1.26 | 1.32 | 1.14 | |
| N‐Acetylphenylalanine | Phenylalanine | 5.1 E‐04 | 1.37 | 1.84 | 1.32 | |
| 3‐Methylglutarylcarnitine | branched chain amino acid | 1.4 E‐03 | 1.59 | 4.67 | 2.26 | |
| N‐Acetylarginine | Arginine/proline | 1.6 E‐03 | 1.87 | 1.56 | 1.27 | |
| Glutarylcarnitine (C5‐DC) | Lysine | 1.6 E‐03 | 1.42 | 2.15 | 1.14 | |
| Gamma‐glutamylmethionine | Gamma‐glutamyl amino acid | 1.6 E‐03 | 0.89 | 0.91 | 0.75 | |
| N‐Acetylleucine | branched chain amino acid | 2.5 E‐03 | 1.29 | 1.13 | 1.24 | |
| Hydroxyasparagine* | Alanine/aspartate | 2.5 E‐03 | 1.37 | 1.82 | 1.25 | |
| N‐Acetylserine | Glycine/serine/threonine | 2.7 E‐03 | 1.48 | 1.85 | 1.17 | |
| Nucleotides | ||||||
| 5,6‐Dihydrouridine | Pyrimidine | 7.4 E‐03 | 1.27 | 2.09 | 1.35 | |
| Orotidine | Pyrimidine | 7.4 E‐03 | 1.50 | 2.46 | 1.23 | |
| Cytidine | Pyrimidine | 7.4 E‐03 | 0.80 | 1.20 | 0.86 | |
| Dihydroorotate | Pyrimidine | 9.6 E‐03 | 1.72 | 1.21 | 1.25 | |
A two‐way ANOVA was performed on log‐transformed data in Metaboanalyst as described in Methods. Fold change at each time point for each individual was calculated on unlogged data. The average fold change for each metabolite in wasting patients was then divided by the average fold change in non‐wasting patients at the same time point to give W/NW. C(x) refers to carbon chain length; DC dicarboxylate; GPC, glycerol phosphsphorylcholine; GPE, glycerol phosphsphorylethanolamine; GPI, glycerol phosphsphorylinositol;
*
metabolite identification by mass spectrum only.